Single-center, open-label, randomized controlled trial comparing the tolerability of maribavir 400 mg twice daily versus standard-dose valganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

American Journal of Transplantation · Elsevier

Аннотация

Publication date: October 2026 Source: American Journal of Transplantation, Volume 26, Issue 10 Author(s): David J. Taber, Hannah Culpepper, Courtney E. Harris, Neha Patel, Morgan Overstreet, Felicia Bartlett, Sakshi Vaishnav, Maria Aurora Posadas Salas, Santosh Nagaraju, Steve Hanish

Читать у издателя →

Похожие статьи